PSMAI cut-off value for mortality in men: 680.1 mm2/m2
Por um escritor misterioso
Descrição
Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
ASCO 2022: PRINCE: Phase I Trial of 177Lu-PSMA-617 in Combination with Pembrolizumab in Patients with mCRPC
Increased prostate cancer specific mortality following radical prostatectomy in men presenting with voiding symptoms—A whole of population study - ScienceDirect
PSMAI cut-off value for mortality in men: 680.1 mm2/m2
Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
Reduced Acquisition Time per Bed Position for PET/MRI Using 68Ga-RM2 or 68Ga-PSMA-11 in Patients With Prostate Cancer: A Retrospective Analysis
Relationship between cut-off point modified PIRO severity score with
Computed tomographic images at the the middle third lumbar vertebral
The Current Landscape of Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy
de
por adulto (o preço varia de acordo com o tamanho do grupo)
